Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - Comparison with historic experience

Hagop Kantarjian*, Moshe Talpaz, Susan O'Brien, Francis Giles, Stefan Faderl, Srdan Verstovsek, Guillermo Garcia-Manero, Jianqin Shan, Mary Beth Rios, Richard Champlin, Marcos De Lima, Jorge Cortes

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

64 Scopus citations

Fingerprint

Dive into the research topics of 'Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia - Comparison with historic experience'. Together they form a unique fingerprint.

Agricultural and Biological Sciences

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science